Clinical trials
Follow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
aFn-uPA
- Development stage
- Preclinical
- Lead developer
- Synapse Research Institute
- Modality
- Nanobodies (VHH) → Antibody Fragments → Engineered Antibody Formats → Antibody-Based Therapeutics, Fc-Fusion Proteins → Carrier/Scaffold Proteins → Recombinant Proteins and Enzymes
- Administration
- Intravenous
01
Overview
aFn-uPA (anti-fibrin urokinase plasminogen activator) is a preclinical-stage recombinant fusion protein designed as a targeted thrombolytic therapy. Developed by Synapse Research Institute and its spinout Mithridate, the construct consists of a urokinase-type plasminogen activator (uPA) genetically fused to a fibrin-specific single-domain antibody (sdAb/nanobody). By targeting fibrin directly without cross-reacting with fibrinogen, aFn-uPA localizes plasminogen activation to the site of a blood clot, thereby enhancing thrombolytic efficacy and reducing systemic bleeding risks compared to standard recombinant tissue-type plasminogen activators (rtPA) like alteplase. It is being investigated for acute thrombotic events, including ischemic stroke, ST-elevation myocardial infarction (STEMI), and pulmonary embolism.
- Other names
- anti-fibrin uPAanti-fibrin-uPAantifibrin urokinase plasminogen activatorfibrin-targeted urokinase fusion protein
02
Targets
Fibrin (Factor Ia)
Beyond the preview
Go deeper on aFn-uPA.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Explore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Trace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Explore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Compare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Connect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on aFn-uPA.